Financial Performance - The company's revenue for Q1 2025 reached ¥1,101,114,916.77, representing a 25.41% increase compared to ¥878,035,956.35 in the same period last year[9] - Net profit attributable to shareholders was ¥91,155,327.04, a significant increase of 62.13% from ¥56,224,262.21 year-on-year[9] - Basic earnings per share rose to ¥0.3094, up 61.65% from ¥0.1914 in the same quarter last year[9] - Total operating revenue for the current period reached ¥1,101,114,916.77, an increase of 25.4% compared to ¥878,035,956.35 in the previous period[25] - Net profit for the current period was ¥102,373,039.07, representing a 57.3% increase from ¥65,054,355.02 in the previous period[28] - Earnings per share (basic) increased to ¥0.3094 from ¥0.1914, reflecting a growth of 61.8%[28] Cash Flow and Liquidity - The net cash flow from operating activities surged to ¥190,488,355.03, marking a 1,541.54% increase from a negative cash flow of ¥13,214,250.87 in the previous year[9] - Cash flow from operating activities was ¥1,291,577,351.67, a significant rise from ¥875,661,091.09 in the previous period[29] - The net cash flow from operating activities was 190,488,355.03, a significant improvement compared to -13,214,250.87 from the previous period, indicating a positive turnaround in operational efficiency[30] - Cash inflow from investment activities totaled 339,079,749.13, down from 470,286,039.88, reflecting a decrease in investment recovery[30] - The net cash flow from financing activities improved to ¥1,826.76 million, a turnaround from a negative cash flow of ¥25,881.90 million in the previous year[17] - The net cash flow from financing activities was 18,267,583.07, recovering from a negative cash flow of -258,819,018.82 in the previous period, showing improved financing conditions[31] - The total cash and cash equivalents at the end of the period reached 854,534,397.37, up from 413,818,117.99, indicating a strong liquidity position[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,575,302,428.28, reflecting a 2.81% increase from ¥4,450,381,119.41 at the end of the previous year[9] - Total current assets increased to ¥2,197,301,192.06 from ¥2,065,843,768.90, reflecting a growth of approximately 6.4%[22] - Cash and cash equivalents at the end of the period amounted to ¥889,889,186.88, up from ¥513,433,433.08, representing a significant increase of 73.4%[22] - Total liabilities decreased slightly to ¥1,830,133,010.34 from ¥1,835,743,722.64, indicating a reduction of 0.3%[24] - The company’s total liabilities increased, with accounts payable slightly decreasing to ¥404,927,429.99 from ¥407,690,460.08[22] Research and Development - The company reported a 58.06% increase in R&D expenses, totaling ¥2,337.58 million, driven by intensified product development efforts[15] - Research and development expenses rose to ¥23,375,814.16, up 58.1% from ¥14,789,530.45 in the previous period, highlighting a focus on innovation[27] Shareholder Information - Total number of common shareholders at the end of the reporting period is 21,855[19] - The largest shareholder, Yantai Zhongxing Biotechnology Co., Ltd., holds 24.80% of shares, totaling 73,125,750 shares[19] Strategic Initiatives - The company is exploring new strategies for market expansion and product development, although specific details were not disclosed in the provided content[19] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[25]

Financial Performance - The company's operating revenue for 2024 reached ¥4,464,751,586.93, representing a 19.15% increase compared to ¥3,747,202,108.57 in 2023[16]. - Net profit attributable to shareholders for 2024 was ¥393,800,766.42, a significant increase of 68.89% from ¥233,163,768.75 in 2023[16]. - The basic earnings per share for 2024 was ¥1.3399, up 67.95% from ¥0.7978 in 2023[16]. - The company's total assets at the end of 2024 were ¥4,450,381,119.41, reflecting a 1.37% increase from ¥4,390,215,978.74 at the end of 2023[16]. - The net cash flow from operating activities for 2024 was ¥496,277,139.83, an 11.02% increase from ¥447,024,832.36 in 2023[16]. - The company reported a weighted average return on equity of 16.80% for 2024, up from 10.88% in 2023, indicating improved profitability[16]. - The total revenue for the year 2024 reached approximately ¥4.46 billion, representing a year-on-year increase of 19.15% compared to ¥3.75 billion in 2023[150]. - Revenue from pet food and supplies accounted for ¥4.29 billion, which is 96.14% of total revenue, showing an 18.78% increase from ¥3.61 billion in the previous year[150]. - The revenue from pet staple food surged by 91.85%, reaching ¥1.11 billion, up from ¥576.76 million in 2023[150]. - The gross profit margin for pet food and supplies improved to 29.13%, reflecting a 2.10% increase from the previous year[151]. Market Position and Growth - The company is positioned in the rapidly growing pet industry, which is expected to continue expanding due to increasing consumer demand and technological advancements[26]. - The global pet care market is projected to reach $207 billion by 2024, with significant growth opportunities in emerging markets[28]. - In the U.S., pet owners' spending on pet products and services is projected to grow by over 67% from 2018 to 2024, reaching a total expenditure of $151.9 billion in 2024[29]. - The European pet market's total consumption reached €53.8 billion in 2023, with pet food sales accounting for €29.2 billion[31]. - Southeast Asia's pet market is expected to exceed $20 billion, with an annual growth rate of 15%[35]. - China's pet industry market size is projected to grow from ¥170.8 billion in 2018 to ¥300.2 billion by 2024, reflecting a growth of 75.76%[37]. - The average annual growth rate of the Chinese pet industry is 32.67%, supported by rising income levels and changing consumer attitudes[43]. - The company aims to focus on domestic market growth while accelerating overseas market expansion, aiming to become a leader in the global pet food industry by 2025[192]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and development strategies, urging investors to understand the differences between plans, forecasts, and commitments[4]. - The company has a comprehensive risk management strategy outlined in the management discussion section, detailing potential operational risks and corresponding countermeasures[4]. - The company faces risks from the complex international political and economic environment, which may impact market demand and overseas business expansion[194]. - The company is exposed to foreign exchange risks due to a significant portion of its revenue being in foreign currencies, primarily USD[197]. - Raw material price fluctuations pose a risk to the company's operating costs, as key materials like chicken and duck meat constitute a large part of its expenses[198]. - Trade tensions, particularly with the U.S., may negatively impact the company's export revenues and profitability[199]. - The company is actively diversifying its market presence and optimizing its cost structure to mitigate risks associated with international competition and trade barriers[195][199]. Research and Development - The company has a leading R&D system with a 12,000 m² research center and over 300 national patents, including 15 invention patents, significantly enhancing production efficiency through a fully digitalized management process[61]. - The company has established strategic partnerships with top research institutions, including the Chinese Academy of Agricultural Sciences, to enhance R&D capabilities in pet food innovation[135][138]. - The number of R&D personnel increased to 286 in 2024 from 198 in 2023, representing a growth of 44.44%[166]. - R&D investment amounted to ¥72,679,350.85 in 2024, up 51.70% from ¥47,909,593.71 in 2023[166]. - The company is developing new pet food products utilizing fermentation technology to enhance nutritional absorption[165]. - The introduction of new plant-based proteins aims to create low-fat pet snacks that meet nutritional needs without causing obesity[166]. - The company is focusing on improving product quality through automated production processes and precise control of key parameters[165]. Production and Operations - The company operates 22 modern production bases globally, including 14 in China and 8 overseas, ensuring local production and regional sales while maintaining a dual traceability system for quality assurance[62]. - The company has established a global sales network, exporting products to 73 countries across five continents, leveraging its stable product quality and strong brand reputation[118]. - The company has invested CNY 230 million to establish a high-end pet wet food factory in New Zealand in 2020[109]. - The company reported a 79% utilization rate for its facilities as of the end of the reporting period[184]. - The company plans to achieve an annual production capacity of 60,000 tons by 2024[184]. - The company is focusing on expanding its market presence through strategic investments and new product development[184]. Brand Development - The company has developed a diverse brand matrix in the domestic market, with brands like "Wanpy," "TOPTREES," and "ZEAL" gaining significant recognition and expanding their market presence through innovative marketing strategies[64]. - The "WANPY" brand, founded in 1998, is recognized as China's first pet food brand to receive the "China Famous Trademark" designation, emphasizing quality, innovation, and fun[77]. - "TOPTREES" has been recognized as the first pet food brand in China to sign a strategic cooperation agreement with CCTV, enhancing its brand credibility[87]. - The "ZEAL" brand, acquired in 2018, has successfully entered over 30 countries, focusing on high-quality, natural pet food products[92]. Investment and Financing - The company issued 7,690,459 convertible bonds in 2022, raising RMB 769,045,900.00, with a net amount of RMB 754,956,277.37 after deducting issuance costs[181]. - The company has committed to specific projects funded by the raised capital, with ongoing assessments of project progress and expected benefits[182]. - The company approved the use of up to RMB 0.15 billion of idle raised funds to temporarily supplement working capital, with a repayment deadline of January 22, 2024[186]. - The company also approved the use of up to RMB 5.10 billion of idle raised funds for temporary working capital and up to RMB 4 billion for cash management, with a 12-month investment period[186].

董事： | 郝忠礼 伊藤范和 江移山 | | --- | | 董海风 张蕴暖 郝宸龙 | | 王欣兰 张晓晓 唐玉才 | | 监事： | | 赵 雷 林 梅 王继成 | | 高级管理人员： | | 肖明岩 朱红新 刘淑清 | | 接元昕 任福照 | 日期： 年 月 日 烟台中宠食品股份有限公司董事、监事、高级管理人员 对 2024 年年度报告的书面确认意见 根据《证券法》第八十二条的要求，本人作为烟台中宠食品股份有限公司的 董事、监事、高级管理人员，保证公司 2024 年年度报告内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或者重大遗漏。 （以下无正文） （此页无正文，为烟台中宠食品股份有限公司董事、监事、高级管理人员对 2024 年年度报告的书面确认意见的签字页） ...

烟台中宠食品股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管 要求（以下简称企业内部控制规范体系），结合本公司内部控制制度和评价办法， 在内部控制日常监督和专项监督的基础上，我们对公司 2024 年 12 月 31 日（内 部控制评价报告基准日）的内部控制有效性进行了评价。 烟台中宠食品股份有限公司 内部控制自我评价报告 烟台中宠食品股份有限公司 2024 年度内部控制自我评价报告 一、 董事会声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价 其有效性并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。管理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证企业经营管理合法合规、资产安全、财务 报告及相关信息真实完整，提高经营效率和效果，促进企业实现发展战略。由于 内部控制存在固有局限性，故仅能为实现上述目标提供合理保证。此外，由于 ...

烟台中宠食品股份有限公司独立董事 第四届董事会第四次独立董事专门会议审查意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》《上市公司独立董事规则》及《烟台中宠食品股份有限公司章程》 等法律、法规和规范性文件的有关规定，作为公司的独立董事，经认真审阅相关 材料，基于独立判断的立场，发表审查意见如下： 一、关于预计公司及子公司 2025 年度日常关联交易的审查意见 公司预计 2025 年度拟发生的日常关联交易为公司发展和日常生产经营所需 的正常交易，符合公司实际情况。上述预计的关联交易不存在损害公司和中小股 东利益的情形，没有违反国家相关法律法规的规定，遵循了公平、公正、公开的 市场交易原则，没有对上市公司独立性产生影响。 （以下无正文） （此页无正文，为烟台中宠食品股份有限公司第四届董事会第四次独立董事 专门会议审查意见的签署页） 全体独立董事： 王欣兰 张晓晓 唐玉才 综上所述，我们认可并同意公司将上述关联交易提交公司第四届董事会第十 五次会议审议。 日期：2025 年 4 月 13 日 ...

债券代码：127076 债券简称：中宠转 2 证券代码：002891 证券简称：中宠股份 公告编号：2025-026 烟台中宠食品股份有限公司 关于 2025 年度对公司及子公司担保额度预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、被担保方情况：本公告所涉及担保的被担保方为烟台中宠食品股份有限 公司（以下简称"公司"）及其子公司，其中烟台顽皮宠物用品销售有限公司（以 下简称"顽皮销售"）、烟台顽皮国际贸易有限公司（以下简称"顽皮国际"） 为公司资产负债率超过 70%的子公司； 2、预计总担保额度超过上市公司最近一期经审计净资产 50%； 公司于 2025 年 4 月 23 日召开第四届董事会第十五次会议、第四届监事会第 十一次会议，审议通过了《关于 2025 年度对公司及子公司担保额度预计的议案》。 具体情况如下： 一、担保情况概述 为满足公司发展需要和日常经营资金需求，根据公司经营目标及总体发展规 划，公司及子公司为公司及子公司提供担保，其中对资产负债率在 70%以上的子 公司，包括顽皮销售、顽皮国际拟申请的担保总额度不超过 ...

烟台中宠食品股份有限公司 2024 年度监事会工作报告 2024 年度，烟台中宠食品股份有限公司（以下简称"公司"）监事会严格 按照《公司法》《公司章程》《监事会议事规则》及有关法律、法规规定，认真 履行监督职责，对公司依法运作、财务管理和关联交易等事项行使了监督检查职 能，公司监事会在维护公司整体利益、股东合法权益、建立健全法人治理结构等 方面进行了有效的监督。现将公司 2024 年度监事会工作情况报告如下： 一、监事会会议情况 本报告期内监事会共召开了 5 次会议，履行监事会的职责，对公司的依法运 作、财务状况、募集资金、关联交易、对外担保、内部控制等方面进行全面监督， 且召开监事会情况如下： 3、募集资金使用情况 | 届次 | 审议事项 | 召开时间 | | --- | --- | --- | | | 1.《关于公司 年年度报告及其摘要的议案》； 2023 7.《关于<2023 年度募集资金存放与使用情况的专项报告>的议案》； | | | | 2.《关于公司 2023 年度监事会工作报告的议案》； | | | | 3.《关于公司 2023 年度财务决算报告的议案》； | | | | 4.《关于公司 20 ...

烟台中宠食品股份有限公司 董事会审计委员会对会计师事务所 2024 年度 履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规和《公司章 程》《董事会审计委员会议事规则》等制度的有关规定和要求，烟台中宠食品股 份有限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的原则，恪尽 职守，认真履职。 现将董事会审计委员会对年审会计师事务所 2024 年度履行监督职责的情况 汇报如下： 一、2024 年年审会计师事务所基本情况 1、基本情况 会计师事务所名称：和信会计师事务所（特殊普通合伙）（以下简称和信会 计师事务所）； 成立日期：1987 年 12 月成立（转制特殊普通合伙时间为 2013 年 4 月 23 日）； 组织形式：特殊普通合伙； 注册地址：济南市文化东路 59 号盐业大厦七楼； 首席合伙人：王晖； 和信会计师事务所上年度经审计的收入总额为 30,165.00 万元，其中审计业 务收入 21,688.00 万元，证券业务收入 ...

Official Wechat YANTAI CHINA PET FOODS CO., LTD 2025-04 NO.88 FEILONG ROAD, LAISHAN ZONE, YANTAI, CHINA / TEL：400-111-8698 / WEB：http://www.wanpy.com.cn YANTAI CHINA PET FOODS ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT About This Report This document constitutes the 2024 Environmental, Social, and Governance (ESG) Report for Yantai China Pet Foods Co., Ltd. (hereafter referred to as "China Pet Foods" or "the Company"). In alignment with the principles of objectivity, standardization, transparency, and comp ...